- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | Longeveron executives to speak at CVCT Forum on cell therapy trials | 1 | Investing.com | ||
| 03.12. | Longeveron: Führungskräfte präsentieren auf Fachforum für Zelltherapie-Studien | 1 | Investing.com Deutsch | ||
| 03.12. | Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum | 1 | GlobeNewswire (USA) | ||
| 02.12. | Longeveron erhält kanadisches Patent für Stammzelltherapie | 1 | Investing.com Deutsch | ||
| 02.12. | Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging | 2 | GlobeNewswire (USA) | ||
| 01.12. | Longeveron's stem cell therapy shows reduced neuroinflammation in AD trial | 3 | Investing.com | ||
| 19.11. | Longeveron stellt Daten zur Alzheimer-Therapie auf der CTAD 2025 vor | 2 | Investing.com Deutsch | ||
| 19.11. | Longeveron to present Alzheimer's treatment data at CTAD 2025 | 1 | Investing.com | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 12.11. | Longeveron secures patent for stem cell therapy targeting aging frailty | 2 | Investing.com | ||
| 12.11. | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | 396 | GlobeNewswire (Europe) | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| 12.11. | Longeveron: Zwei Vorstandsmitglieder legen Ämter nieder | 4 | Investing.com Deutsch | ||
| 12.11. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.11. | Longeveron GAAP EPS of -$0.39 misses by $0.13, revenue of $125M beats by $124.71M | 2 | Seeking Alpha | ||
| 04.11. | Longeveron Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | Earnings Preview For Longeveron | 2 | Benzinga.com | ||
| 27.10. | Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect | 1 | GlobeNewswire (USA) | ||
| 01.10. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Longeveron beruft Teamarzt der St. Louis Cardinals in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 01.10. | George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron Board of Directors | 1 | GlobeNewswire (USA) | ||
| 22.09. | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,262 | -1,02 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| CRISPR THERAPEUTICS | 48,200 | 0,00 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| OCUGEN | 1,178 | +0,51 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | ||
| EDITAS MEDICINE | 2,156 | -0,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CYTODYN | 0,250 | -13,19 % | CytoDyn Inc.: CytoDyn Announces Resolution of Class Action Lawsuit | VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,008 | +7,69 % | SOL Global Investments Corp.: SOL Global Announces Share Consolidation | Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors... ► Artikel lesen | |
| TRINITY BIOTECH | 0,949 | -10,49 % | Trinity Biotech-Aktie legt zu: Neues HbA1c-System erhält weitere Marktzulassungen | ||
| FATE THERAPEUTICS | 0,933 | -5,14 % | Fate Therapeutics, Inc.: Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs | ||
| ANAVEX LIFE SCIENCES | 3,510 | +2,63 % | Anavex Life Sciences Corp.: Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease | NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,220 | -3,22 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| CERUS | 1,750 | -5,56 % | Cerus signs purchasing agreement with Blood Centers of America | ||
| OVID THERAPEUTICS | 1,300 | -7,80 % | Ovid Therapeutics: Aktionäre genehmigen Erhöhung der genehmigten Aktien und weitere Anträge | ||
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,060 | -6,19 % | Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 | 100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,630 | -0,79 % | Harvard Bioscience, Inc.: Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States | HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a leading provider of innovative laboratory equipment, is pleased... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,049 (-8,18 %) liegt der Kurs bei 0,553 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.